Intellectual Product
Inventiva Halts Enrollment in Phase 3 MASH Study Following Patient Raised Liver Enzyme Incident
Clinical Research, lanifibranor, Incident
FDA Awaits Final Decision on Madrigal’s Resmetirom for NASH Treatment with Priority Review and NDA Acceptance Set for March 14, 2024
Nonalcoholic Steatohepatitis, resmetirom, United States Food and Drug Administration, New Drug Application, Priority Review, Fibrosis, Liver, Liver, Madrigal’s, March 14, 2024
Jazz Pharmaceuticals Expands Oncology Pipeline with Redx’s KRAS Inhibitor Program
Kirsten murine sarcoma virus, Jazz, Redx, Inhibitor
After Incyte’s commercial buy, Novartis shells out 2.7B for cancer specialist MorphoSys
Importal, MorphoSys, Acquisition (action), Incyte
UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
Cystic Fibrosis, Trikafta, vanza, Vertex, next-gen, Records
Takeda Reports Lower Profits in Latest Quarter, Closes $300M Deal with Protagonist
Protagonist, profit, Takeda, Quarter, Report (document), earnings, Takeda’s
Novo Nordisk Gets 2023 Profit Beat Fueled by Ozempic, Wegovy Sales Spike
Nordisk, Ozempic, Constant – dosing instruction fragment, exchange rate
FDA rejects Defender’s motion sickness treatment
United States Food and Drug Administration, Safety, Effectiveness
Lonza closes plant in China but CDMO’s sales signal an uptick in industry
Plants, China, Signal, Industry, Congestive heart failure